Skip to main content

Peer Review reports

From: Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with Advanced COloRectal cancer RAS or BRAF mutated – NIVACOR trial (GOIRC-03-2018)

Original Submission
8 Apr 2020 Submitted Original manuscript
14 May 2020 Reviewed Reviewer Report
3 Jul 2020 Reviewed Reviewer Report - Enrique Aranda
13 Jul 2020 Author responded Author comments - Angela Damato
Resubmission - Version 2
13 Jul 2020 Submitted Manuscript version 2
19 Jul 2020 Author responded Author comments - Angela Damato
Resubmission - Version 3
19 Jul 2020 Submitted Manuscript version 3
23 Jul 2020 Author responded Author comments - Angela Damato
Resubmission - Version 4
23 Jul 2020 Submitted Manuscript version 4
26 Jul 2020 Author responded Author comments - Angela Damato
Resubmission - Version 5
26 Jul 2020 Submitted Manuscript version 5
5 Aug 2020 Author responded Author comments - Angela Damato
Resubmission - Version 6
5 Aug 2020 Submitted Manuscript version 6
Publishing
6 Aug 2020 Editorially accepted
31 Aug 2020 Article published 10.1186/s12885-020-07268-4

You can find further information about peer review here.

Back to article page